Patents matching “ONC”

US 9522910

Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon

OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” · Granted Dec 20, 2016 · Expires Dec 15, 2036

US 9504730

Method of achieving a thymosin beta 4 concentration in a human patient

REGENERX BIOPHARMACEUTICALS, INC. · Granted Nov 29, 2016 · Expires Nov 24, 2036

US 9408820

Broncholytic drug on the basis of prostaglandin

OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU “NOXI LAB” · Granted Aug 9, 2016 · Expires Aug 4, 2036

US 9399662

Concurrent chemotherapy and immunotherapy

The Board of Regents of the University of Texas System · Granted Jul 26, 2016 · Expires Jul 21, 2036

US 9370519

Macrocyclic FLT3 kinase inhibitors

Oncodesign SA · Granted Jun 21, 2016 · Expires Jun 16, 2036

US 9365823

Virus clearance of neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Jun 14, 2016 · Expires Jun 9, 2036

US 9328142

Lipopeptide inhibitors of RAS oncoproteins

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 3, 2016 · Expires Apr 28, 2036

US 9289408

High concentration baclofen preparations

The Board of Regents of the University of Texas System · Granted Mar 22, 2016 · Expires Mar 17, 2036

US 9241998

Methods and compositions for treatment of cancer using oncolytic RSV activity

The Board of Regents of the University of Texas System · Granted Jan 26, 2016 · Expires Jan 21, 2036

US 9198453

Methods of reducing blood lactate concentration

Stokely-Van Camp, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

US 9120967

Concentric forster resonance energy transfer relay for the parallel detection of two bio/physicochemical process

United States of America as represented by the Secretary of the Air Force · Granted Sep 1, 2015 · Expires Aug 27, 2035

US 9107912

Methods for concomitant treatment of theophylline and febuxostat

Takeda Pharmaceuticals U.S.A., Inc. · Granted Aug 18, 2015 · Expires Aug 13, 2035

US 9096609

Macrocyclic LRRK2 kinase inhibitors

Oncodesign SA · Granted Aug 4, 2015 · Expires Jul 30, 2035

US 9090630

Macrocyclic FLT3 kinase inhibitors

Oncodesign SA · Granted Jul 28, 2015 · Expires Jul 23, 2035

US 9061055

Oncolytic adenovirus armed with therapeutic genes

The Board of Regents of the University of Texas System · Granted Jun 23, 2015 · Expires Jun 18, 2035

US 9044498

Lyophilized viral formulations

ONCOLYTICS BIOTECH INC. · Granted Jun 2, 2015 · Expires May 28, 2035

US 9045728

Liquid viral formulations

ONCOLYTICS BIOTECH INC. · Granted Jun 2, 2015 · Expires May 28, 2035

US 8906353

Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Nektar Therapeutics · Granted Dec 9, 2014 · Expires Dec 4, 2034

US 8883841

Oncogenic ras-specific cytotoxic compound and methods of use thereof

The Board of Regents of the University of Texas System · Granted Nov 11, 2014 · Expires Nov 6, 2034

US 8822698

Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family

Oreste Piccolo Studio di Consulenza Scientifica · Granted Sep 2, 2014 · Expires Aug 28, 2034

US 8785191

Concentration of stem cells obtained during orthopaedic surgeries

UNIVERSITY OF CONNECTICUT · Granted Jul 22, 2014 · Expires Jul 17, 2034

US 8779094

Low viscosity highly concentrated suspensions

The Board of Regents of the University of Texas System · Granted Jul 15, 2014 · Expires Jul 10, 2034

US 8722646

High concentration chitosan-nucleic acid polyplex compositions

ENGENE, INC. · Granted May 13, 2014 · Expires May 8, 2034

US 8716287

Pharmaceutical compounds

SENTINEL ONCOLOGY LIMITED · Granted May 6, 2014 · Expires May 1, 2034